CryoStasis
A platform that stores cells unfrozen at subzero temperatures, eliminating cryoprotectants and liquid nitrogen for cell‑therapy and transplant applications.
Private Company
Estimated funding: $8M
AI Company Overview
A platform that stores cells unfrozen at subzero temperatures, eliminating cryoprotectants and liquid nitrogen for cell‑therapy and transplant applications.
Technology Platform
A Subzero Unfrozen (SU) preservation system combining chemically defined media, precise subzero temperature control, and high‑pressure induced stasis to store cells indefinitely without cryoprotectants or liquid nitrogen.
Opportunities
Risk Factors
Competitive Landscape
Key competitors include Thermo Fisher Scientific, BioLife Solutions, and Lonza, which rely on conventional freezing; CryoStasis differentiates through its unfrozen subzero approach, potentially offering higher viability and logistical simplicity.